Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Gattex teduglutide: Phase III data

In a double-blind, international Phase III trial (CL0600-004) in 83 patients, the high-dose of Gattex (0.1 mg/kg/day) missed the primary

Read the full 200 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE